Catyalyst Pharma (CPRX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 9, 2017 4:30 PM EDTCORAL GABLES, Fla., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2017 and provided a corporate update.
We continue to make progress towards completion of enrollment in our confirmatory Phase 3 trial of Firdapse® in LEMS patients, said Patrick J. McEnany, Chief Executive Officer of Catalyst. We look forward to receiving top-line results from our Phase 3 trial, and assuming... More
